Results · Apr-Jun 2026 · filed 13 Aug 2026
Gaudium IVF and Women Health Q1 FY27 results
Sales grew 9% to ₹19.4 crore from ₹17.8 crore in Apr-Jun 2025.
Operating profit was ₹2.4 crore, an operating margin of 12.5%.
Net profit fell 42% to ₹1.8 crore from ₹3.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −36%, net profit −79%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 19.4 | 17.8 | +9% |
| Operating profit (EBITDA) | 2.4 | - | - |
| Operating margin | 12.5% | - | - |
| Net profit | 1.8 | 3.1 | −42% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew 9.1% to ₹19.4 crore but profit fell as management invested heavily in expansion & AI technology marketing. Management guided 30% FY27 revenue growth & sustained margins by year-end.
The last 4 quarters
Filings that week
- 19 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 13 Aug 2026Statement Of Deviation & Variation For The Quarter Ended June 30, 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.